pharmaphorum July 30, 2024
mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma.
The study is looking at the combination of BNT111 with Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) in 184 patients with advanced melanoma who have relapsed after or not responded to treatment with a PD-1/PD-L1 inhibitor, or the two therapies given alone.
There was a statistically significant improvement in the overall response rate (ORR) for the combination compared to historical controls like anti-PD-1/PD-L1 and anti-CTLA4 drugs, while BNT111 and Libtayo monotherapy also showed evidence of clinical activity, according to BioNTech.
BNT111 is a key part of the German biotech’s pipeline and development strategy as...
Today's Sponsors
Today's Sponsor